FOD announces distribution proposal and investment deal with Careline Australia

The Food Revolution Group has proposed strategic distribution agreement with health and skin care products exporter Careline Australia Pty Ltd to distribute FOD products in China, targeting additional sales of at least $20 million per annum within two years. The deal is in exchange of up to 190 million shares issued by FOD to Caroline once the agreement is through.

 As per the company’s announcement to ASX, Careline will distribute FOD’s beverages, juice, and vitamin products in China to rapidly boost the sale of The Food Revolution Group from approximately A$35 million to between A$100M and A$500 million within three to five years. 

Further, FOD has inked an investment deal with founder and CEO of Careline Australia Pty Ltd, Dr. Norman Li to invest up to $20.25 million. The investment is reported to be done in five tranches through the issue of 375 million shares at an issue price of $0.054 per share. Following the completion of Tranche 2 investment, strategic investor Dr Norman Li is expected to be appointed as a Chairman of The Food Revolution Group.

This would enable FOD to expand its sales and distribution of existing as well as new products by utilizing Careline’s growing network of more than 10,000 affiliate marketers.

FOD is expected to enter into the distribution agreement on 28 September 2018 after receiving due approval from its shareholders.

Following the announcement of investment and proposed distribution agreements FOD share price has gone down by 3.125% to $0.093 on 11 September 2018 (2:20 PM AEST). The stock has seen a performance change of +84.62% over the past one year.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report